Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype
Latest Information Update: 13 Oct 2023
At a glance
- Drugs Bexarotene (Primary) ; Capecitabine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Pharmacodynamics
- Acronyms BEXMET
- 09 Oct 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2025.
- 09 Oct 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Sep 2024.
- 17 Dec 2020 New trial record